Abstract: Provided are the crystalline solid meglumine salts of (R)-5-(4-chlorophenyl)-1-isopropyl-2-methyl-4-(3-(4-(4-((4-((1-(phenylthio)-4-(4-((phosphonooxy)methyl)piperidin-1-yl)butan-2-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonamido)phenyl) piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylic acid. Pharmaceutical compositions having one or more of the crystalline solid meglumine salt compounds and methods for administering the crystalline solid meglumine salt compounds to a subject are also described. Methods for preparing the crystalline solid meglumine salt compounds are also provided.

Abstract: Described herein are polymorphs comprising 2?,6-difluoro-5?-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b][1,2,4]tri-azin-7-yl]biphenyl-2-carbonitrile (TPA023B) or salts thereof. In one aspect, disclosed herein is a crystalline polymorphic salt or co-crystal of TPA023B with phosphoric acid. In another aspect, disclosed herein is a crystalline polymorphic salt or co-crystal of TPA023B with sulfuric acid. Also described herein are methods of making and using the same.